©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 28, 2015; 7(24): 2543-2550
Published online Oct 28, 2015. doi: 10.4254/wjh.v7.i24.2543
Published online Oct 28, 2015. doi: 10.4254/wjh.v7.i24.2543
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
James Fung, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, China
James Fung, Liver Transplant Center, Queen Mary Hospital, Hong Kong, China
James Fung, State Key Laboratory for Liver Research, the University of Hong Kong, Hong Kong, China
Author contributions: Fung J solely contributed to this work.
Conflict-of-interest statement: None.
Correspondence to: James Fung, Consultant, Honorary Clinical Associate Professor, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, 102 Pokfulam Road, Hong Kong, China. jfung@gastro.hk
Telephone: +852-2-2553830 Fax: +852-2-8725828
Received: May 4, 2015
Peer-review started: May 5, 2015
First decision: June 3, 2015
Revised: September 7, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: October 28, 2015
Processing time: 179 Days and 0.6 Hours
Peer-review started: May 5, 2015
First decision: June 3, 2015
Revised: September 7, 2015
Accepted: October 12, 2015
Article in press: October 13, 2015
Published online: October 28, 2015
Processing time: 179 Days and 0.6 Hours
Core Tip
Core tip: Chronic hepatitis C has become an easily curable disease with new direct acting antivirals (DAAs). However, due to multiple barriers to therapy, only those with highest unmet clinical needs including those with prior treatment failure, cirrhosis, and post-liver transplant, will likely receive therapy. DAAs have been shown to be highly efficacious in these groups.